By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyse site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
Coffee & Health
Part of
Neurodegenerative disorders
More information
Affects of coffee consumption
  1. Swift C.G. & Tiplady B. (1988): The effects of age on the response to caffeine. Psychopharmacology, 94:29-31.
  2. Rees K. et al. (1999): The influences of age and caffeine on psychomotor and cognitive function. Psychopharmacology, 145:181-188.
  3. Hogervorst E. et al. (1998): Caffeine improves memory performance during distraction in middle-aged, but not in young or old subjects. Hum Psychopharmacol, 13:277-284.
  4. Lorist M.M. et al. (1995): Aging, caffeine, and information processing: an event-related potential analysis. Electroencephalogr Clin Neurophysiol, 96:453-467.
  5. Jarvis M.J. (1993): Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology, 110:45-52.
  6. Beydoun M.A. et al. (2014): Caffeine and Alcohol Intakes and Overall Nutrient Adequacy Are Associated with Longitudinal Cognitive Performance among U.S. Adults. J Nutr, 144(6):890-901.
  7. Hameleers P.A. et al. (2000): Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Hum Psychopharmacol, 15:573-581.
  8. van Hooren S.A. et al. (2005): Influence of cognitive functioning on functional status in an older population: 3- and 6-year follow-up of the Maastricht Aging Study. Int J Geriatr Psychiatry, 20:883-888.
  9. Cropley V. et al. (2011): Does coffee enriched with chlorogenic acids improve mood and cognition after acute administration in healthy elderly? A pilot study.Psychopharmacology, 219(3):737-49.
  10. Santos C. et al. (2010): Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis, 20 Suppl 1:S187-204.
  11. Arab L. et al. (2013): Epidemiologic Evidence of a Relationship between Tea, Coffee, or Caffeine Consumption and Cognitive Decline. Adv Nutr, vol. 4:115-122.
  12. Larsson S.C., Orsini N. (2018): Coffee Consumption and Risk of Dementia and Alzheimer’s Disease: A Dose-response Meta-Analysis of Prospective Studies. Nutrients, Volume 10 (10).
  13. Johnson-Kozlow M. et al. (2002): Coffee consumption and cognitive function among older adults. Am J Epidemiol, 156:842-850.
  14. Ritchie K. et al. (2007): The neuroprotective effects of caffeine: a prospective population study (the Three City Study).Neurology, 69:536-545.
  15. Santos C. et al. (2010): Caffeine intake is associated with a lower risk of cognitive decline: a cohort study from Portugal. J Alzheimers Dis, 20 Suppl 1:S175-85.
  16. Arab L. et al. (2011): Gender Differences in Tea, Coffee, and Cognitive Decline in the Elderly: The Cardiovascular Health Study. J Alzheimers Dis, 2011;27(3):553-66.
  17. van Gelder B.M. et al. (2007): Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr, 61:226-32.
  18. Corley J. et al. (2010): Caffeine consumption and cognitive function at age 70: The Lothian birth cohort 1936 study. Psychosom Med, 72:206-14.
  19. Wu M.S. et al. (2011): Socio-demographic and health-related factors associated with cognitive impairment in the elderly in Taiwan. BMC Public Health, 11:22.
  20. Vercambre M.-N. et al. (2013): Caffeine and Cognitive Decline in Elderly Women at High Vascular Risk. J Alzheimers Dis, 35(2):413-21.
  21. Wu L. et al. (2016): Coffee Intake and the Incident Risk of Cognitive Disorders: A Dose-response Meta-Analysis of Nine Prospective Cohort Studies. Clin Nutr, 36(3):730-736.
  22. Liu Q.-P. et al. (2016): Habitual coffee consumption and risk of cognitive decline/dementia: A systematic review and meta-analysis of prospective cohort studies. Nutr, 32(6):628-36.
  23. EFSA (2015): Scientific Opinion on the Safety of Caffeine, EFSA Journal, 13(5):4102.
  24. Cao C. et al. (2012): High blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis, 30:559-572.
  25. Maia L & de Mendonça A. (2002): Does caffeine intake protect from Alzheimer’s disease? Eur J Neurol, 9:377-82.
  26. Lindsay J. et al. (2002): Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol, 156:445-53.
  27. Broe G.A. et al. (1990): A case-control study of Alzheimer’s disease in Australia. Neurology, 40:1698-707.
  28. Tyas S.L. et al. (2001): Risk factors for Alzheimer’s disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol; 30:590-7.
  29. Barranco Quintana J.L. et al. (2007): Alzheimer’s disease and coffee: a quantitative review. Neurol Res, 29:91-5.
  30. Eskelinen M.H, Kivipelto M. (2010): Caffeine as a protective factor in dementia and Alzheimer’s disease. J Alz Dis, 20 Suppl 1:S167-74
  31. Wierzejska R. (2017): Can coffee consumption lower the risk of Alzheimer’s disease and Parkinson’s disease? A literature review. Arch Med Sci, Volume 13 (3)
  32. Larsson S.C. et al. (2017): Modifiable pathways in Alzheimer’ s disease: Mendelian randomisation analysis. BMJ, 359:j5375.
  33. Eskelinen M.H. et al. (2009): Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis, 16:85-91.
  34. Laitala V.S. et al. (2009): Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr, 90:640-6.
  35. Gelber R.P. et al. (2011): Coffee intake in midlife and risk of dementia and its neuropathologic correlates. J Alzheimers Dis, 23:607-15.
  36. Arendash G.W. et al. (2006): Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain β-amyloid production. Neuroscience, 142:941-52.
  37. Arendash G.W. et al. (2009): Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer’s disease mice. J Alzheimers Dis, 17:661-80.
  38. Cao C. et al. (2009): Caffeine suppresses amyloid-β levels in plasma and brain of Alzheimer’s disease transgenic mice.J Alzheimers Dis, 17:681-97.
  39. Cao C. et al. (2011): Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer’s mice. J Alzheimers Dis, 25(2):323-35.
  40. Han M.E. et al. (2009): Regulation of cerebrospinal fluid production by caffeine consumption. BMC Neurosci, 10:110.
  41. Wostyn P. et al. (2011): Increased cerebrospinal fluid production as a possible mechanism underlying caffeine’s protective effect against Alzheimer’s disease. Int J Alzheimers Dis, 2011:617420.
  42. Madeira M.H. et al. (2017): Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases. Mediators Inflamm, 2017:4761081.
  43. Tohda C. et al. (2005): Search for natural products related to regeneration of the neuronal network. Neurosignals, 14:34-45.
  44. Tohda C. et al. (1999): Trigonelline-induced neurite outgrowth in human neuroblastoma SK-N-SH cells. Biol Pharm Bul, 22:679-82.
  45. Kim H.S. et al. (2004): Inhibitory effects of long-term administration of ferulic acid on microglial activation induced by intracerebroventricular injection of beta-amyloid peptide (1-42) in mice. Biol Pharm Bull, 27:120-1.
  46. Cho J.Y. et al. (2005): Inhibitory effects of long-term administration of ferulic acid on astrocyte activation induced by intracerebroventricular injection of beta-amyloid peptide (1-42) in mice. Prog Neuropsychopharmacol Biol Psychiatry, 29:901-7.
  47. Nefzger M.D. et al. (1968): A retrospective study of smoking in Parkinson’s disease. Am J Epidemiol, 88:149-158.
  48. Jimenez-Jimenez F.J. et al. (1992): Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson’s disease: a case-control study. Mov Disord, 7:339-44.
  49. Fall P.A. et al. (1999): Nutritional and occupational factors influencing the risk of Parkinson’s disease: a case-control study in southeastern Sweden. Mov Disord, 14:28-37.
  50. Hellenbrand W. et al. (1996): Diet and Parkinson’s disease. I. A possible role for the past intake of specific foods. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology, 47:636-43.
  51. Webster Ross G. et al. (2000): Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA, 283:2674-2679.
  52. van der Mark M. et al. (2014): A Case-Control Study of the Protective Effect of Alcohol, Coffee, and Cigarette Consumption on Parkinson Disease Risk: Time-Since-Cessation Modifies the Effect of Tobacco Smoking,PLoS One, 9(4):e95297.
  53. Hernan M.A. et al. (2002): A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol, 52:276-84.
  54. Costa J. et al. (2010): Caffeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis, 20 Suppl 1:S221-38.
  55. Liu R. et al. (2012): Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol, 175(11):1200-7.
  56. Qi H. et al. (2014): Dose–response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatr Gerontol Int, (2):430-9.
  57. Ascherio A. et al. (2001): Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol, 50:56-63.
  58. Ascherio A. et al. (2003): Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology, 60:790-5.
  59. Palacios N. et al. (2012): Caffeine and Risk of Parkinson’s Disease in a Large Cohort of Men and Women.Movement Disorders, 27(10):1276-82.
  60. Palacios N. et al. (2010): Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson’s disease in men and women. Parkinsonism Relat Disord, 16:370-5.
  61. Kim I.Y. et al. (2017): Differences in Parkinson’s Disease Risk with Caffeine Intake and Postmenopausal Hormone Use, J Parkinsons Dis, 7(4):677-684.
  62. Postuma R.B. et al. (2012): Caffeine for treatment of Parkinson disease: A randomized controlled trial. Neurology, 79(7): 651–658.
  63. Cho B.H. et al. (2018): Association of Coffee Drinking and Non-motor Symptoms in Drug Naive, Early Stage Parkinson’s Disease, Parkinsonism & Related Disorders,50:42-47.
  64. Kuwana Y. et al. (1999): Antiparkinsonian activity of adenosine A2A antagonists in experimental models.Adv Neurol, 80:121-3.
  65. Fenu S. & Morelli M. (1998): Motor stimulant effects of caffeine in 6-hydroxydopamine-lesioned rats are dependent on previous stimulation of dopamine receptors: a different role of D1 and D2 receptors. Eur J Neurosci, 10:1878-84.
  66. Chen J.F. et al. (2001): Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci, 21:RC143.
  67. Morelli M. et al. (2009): Adenosine A2A receptors and Parkinson’s disease.Handb Exp Pharmacol, 193:589-615.
  68. Iida M. et al. (1999): Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res, 838:51-9.
  69. Chuang Y.H. et al. (2017): Gene-Environment Interaction in Parkinson’s Disease: Coffee, ADORA2A, and CYP1A2. Neuroepidemiol, 47(3-4):192-200
  70. Kim I.Y. et al. (2018): Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson’s disease risk. Mov Disord, 33(3):414-420.
  71. Larsson S.C. et al. (2008): Coffee and tea consumption and risk of stroke subtypes in male smokers. Stroke, 39:1681-7.
  72. Larsson S.C. et al. (2011): Coffee consumption and risk of stroke in women. Stroke, 42:908-12.
  73. Lopez-Garcia E. et al. (2009): Coffee consumption and risk of stroke in women.Circulation, 119:1116-23.
  74. Larsson S.C. & Orsini N. (2011): Coffee consumption and risk of stroke: A dose-response meta-analysis of prospective studies. Am J Epidemiol, 174(9):993-1001.
  75. Piriyawat P. et al. (2003): Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischemic stroke. Stroke, 34:1242-5.
  76. Deng C. et al.(2017): Stroke and food groups: an overview of systematic reviews and meta-analyses. Pub Health Nutr, 21(4):766-776.
  77. Singh-Manoux A. et al. (2011): Timing of onset of cognitive decline: results from Whitehall II prospective cohort study.BMJ, 343:d7622.
  78. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2011): Scientific Opinion on the substantiation of health claims related to caffeine and increased fat oxidation leading to a reduction in body fat mass (ID 735, 1484), increased energy expenditure leading to a reduction in body weight (ID 1487), increased alertness (ID 736, 1101, 1187, 1485, 1491, 2063, 2103) and increased attention (ID 736, 1485, 1491, 2375) pursuant to Article 13(1) of Regulation (EC) No 1924/20061. EFSA Journal, 9(4):2054.
  79. Nehlig A. (2010): Is Caffeine a Cognitive Enhancer? J Alzheimers Dis, 20(S1):85-94.
  80. McLellan T.M. et al. (2016): A review of caffeine’s effects on cognitive, physical and occupational performance. Neuro & Biobehav Revs, 71:294-312.
  81. Ryan L. et al. (2002): Caffeine reduces time-of-day effects on memory performance in older adults. Psychol Sci, 13:68-71.
  82. Smith A.P. (1994): Caffeine, performance, mood and status of reduced alertness. Pharmacopsychoecologia, 7:75-86.
  83. Smith A.P. (2005): Caffeine inNutritional Neuroscience, Lieberman H, Kanarek R, Prasad C, eds. Taylor & Francis, Boca Raton, FL;pp. 335-359.
  84. Alzheimer Europe (2019): ‘Alzheimer’s disease. Available at:
  85. Alzheimer Europe (2019): ‘Who is affected by Alzheimer’s disease?’ Available at:
  86. GBD Dementia Collaborators (2016): Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 18(1): 88-106.
  87. Alzheimer’s Disease International (2015): World Alzheimer Report 2015 The Global Impact of Dementia- An AnalysIs of prevalence, Incidence, cost and trends. Available at:
  88. Alzheimer Europe (2013): ‘Prevalence of dementia in Europe’ Available at:
  89. O’Brien R.J., Wong P.C. (2011): Amyloid Precursor Protein Processing and Alzheimer’s Disease. Ann Rev Neurosci, 34:185-204.
  90. Ray Dorsay E. et al. (2018): Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 17(11):939-953.
  91. European Parkinson’s Disease Association ‘What is Parkinson’s’ Available at:
  92. World Heart Federation, ‘Cardiovascular Health: Stroke’ Available at:

Latest research

All research

Information campaigns

All information campaigns